Status:
COMPLETED
Open Label Extension Study of Bifeprunox
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-66 years
Phase:
PHASE3
Brief Summary
A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
Eligibility Criteria
Inclusion
- Outpatients who have successfully completed Wyeth study 3168A1-311-US.
- A signed and dated informed consent form for this study.
- No major protocol violations in previous study.
Exclusion
- Clinically important abnormalities noted in preceding short-term study that have not resolved.
- Use of prohibited treatments in the preceding short-term study.
- Meeting any exclusion criteria for the preceding short-term study.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00366171
Start Date
November 1 2006
End Date
October 1 2007
Last Update
December 27 2007
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72201
2
Little Rock, Arkansas, United States, 72211
3
Anaheim, California, United States, 92802
4
Anaheim, California, United States, 92804